Your browser doesn't support javascript.
loading
Positive Ratio of Polymerase Chain Reaction (PCR) and Validity of Pre-Screening Criteria at an Outpatient Screening Center during the Early Phase of the COVID-19 Epidemic in Japan.
Ide, Satoshi; Hayakawa, Kayoko; Yamamoto, Kei; Tsuzuki, Shinya; Tanuma, Junko; Ohara, Kaori; Yamada, Gen; Okuhama, Ayako; Kanda, Kohei; Suzuki, Tetsuya; Akiyama, Yutaro; Miyazato, Yusuke; Nakamura, Keiji; Nomoto, Hidetoshi; Nakamoto, Takato; Ujiie, Mugen; Saito, Sho; Morioka, Shinichiro; Ishikane, Masahiro; Kinoshita, Noriko; Kutsuna, Satoshi; Tanaka, Keiko; Ohmagari, Norio.
Afiliação
  • Ide S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Hayakawa K; Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan.
  • Yamamoto K; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Tsuzuki S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Tanuma J; AMR Clinical Reference Center, National Center for Global Health and Medicine, Japan.
  • Ohara K; Faculty of Medicine and Health Sciences, University of Antwerp, Belgium.
  • Yamada G; AIDS Clinical Center, National Center for Global Health and Medicine, Japan.
  • Okuhama A; Bureau of International Health Cooperation, National Center for Global Health and Medicine, Japan.
  • Kanda K; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Suzuki T; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Akiyama Y; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Miyazato Y; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Nakamura K; Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan.
  • Nomoto H; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Nakamoto T; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Ujiie M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Saito S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Morioka S; Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan.
  • Ishikane M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Kinoshita N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Kutsuna S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Tanaka K; Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
Jpn J Infect Dis ; 74(5): 481-486, 2021 Sep 22.
Article em En | MEDLINE | ID: mdl-33642432
ABSTRACT
Despite the increase in COVID-19 cases globally, the number of cases in Japan has been relatively low, and an explosive surge in the prevalence has not occurred. In March 2020, the Ministry of Health, Labour and Welfare (MHLW) in Japan recommended the original criteria for polymerase chain reaction (PCR) testing, although there was a lack of evidence for appropriate targets for COVID-19 testing. This study aimed to evaluate the COVID-19 positive ratio and pre-screening criteria in Tokyo immediately after the insurance-covered SARS-CoV-2 PCR testing became available in Japan. We subjected 277 individuals with mild symptoms in metropolitan Tokyo (positive 9.0%) from March 9 to 29, 2020, to SARS-CoV-2 PCR testing. The results revealed that 25 (9.0%) of them were PCR-positive. The sensitivity and specificity of the MHLW criteria were 100% and 10.7%, respectively. When the criteria excluded nonspecific symptoms, fatigue, and dyspnea, the sensitivity slightly decreased to 92%, and the specificity increased to 22.2%. The specificity was highest when the fever criterion was ≥37.5°C for ≥4 days, and exposure/travel history, including age and underlying comorbidities, was considered. Our findings suggest that the MHLW criteria, including the symptoms and exposure/travel history, may be useful for COVID-19 pre-screening.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Programas de Rastreamento / Teste de Ácido Nucleico para COVID-19 / SARS-CoV-2 / COVID-19 Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Jpn J Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Programas de Rastreamento / Teste de Ácido Nucleico para COVID-19 / SARS-CoV-2 / COVID-19 Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Jpn J Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão